Not available
Quote | Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
Last: | $25.77 |
---|---|
Change Percent: | 0.23% |
Open: | $26.49 |
Close: | $25.77 |
High: | $26.49 |
Low: | $25.66 |
Volume: | 270,159 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
2024-07-02 07:30:00 ET Summary Supernus' revenue growth is hindered by rapidly declining Trokendi sales. There are no pipeline products reliably poised to help out with revenues. Qelbree provides the one bright point on Supernus' revenues. This is my eighth Supernus ( ...
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
Message Board Posts | Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
Subject | By | Source | When |
---|---|---|---|
Just found this one - Well over a | ncstrongman | investorshub | 04/11/2022 12:49:30 PM |
I hope everyone got some 28 es because | ball8281 | investorshub | 12/23/2020 1:24:09 AM |
Wow thats amazing news tomorrow gap up will | ball8281 | investorshub | 12/23/2020 1:23:21 AM |
Boom were heading to 50 dollars a share tomorrow | ball8281 | investorshub | 12/23/2020 1:22:53 AM |
what about the PDUFA on the 8th? will | Diwanssong | investorshub | 11/06/2020 4:54:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
2024-05-24 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharm...